Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer

[1]  Mingwei Liu,et al.  Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma , 2019, Nature.

[2]  X. Xing,et al.  Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine. , 2019, Journal of proteomics.

[3]  D. Park,et al.  Proteogenomic Characterization of Human Early-Onset Gastric Cancer. , 2019, Cancer cell.

[4]  T. Hirota,et al.  Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth , 2019, Science Advances.

[5]  F. He,et al.  Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer , 2018, EBioMedicine.

[6]  Matthias Mann,et al.  In vivo brain GPCR signaling elucidated by phosphoproteomics , 2018, Science.

[7]  N. Gray,et al.  Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.

[8]  Mingwei Liu,et al.  A proteomic landscape of diffuse-type gastric cancer , 2018, Nature Communications.

[9]  J. Blenis,et al.  Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling , 2017, Cell.

[10]  Paul Shapiro,et al.  Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib) , 2017, Molecular Cancer Therapeutics.

[11]  M. Ellis,et al.  CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.

[12]  H. Bae,et al.  Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology , 2017, World journal of gastrointestinal oncology.

[13]  Alberto Puliafito,et al.  PDK1: At the crossroad of cancer signaling pathways. , 2017, Seminars in cancer biology.

[14]  Jun Qin,et al.  Firmiana: towards a one-stop proteomic cloud platform for data processing and analysis , 2017, Nature Biotechnology.

[15]  P. Cutillas,et al.  Impact of phosphoproteomics in the translation of kinase‐targeted therapies , 2017, Proteomics.

[16]  Pedro Beltrão,et al.  Benchmarking substrate-based kinase activity inference using phosphoproteomic data , 2016, bioRxiv.

[17]  Omar Abdel-Wahab,et al.  Therapeutic targeting of splicing in cancer , 2016, Nature Medicine.

[18]  Evan O. Paull,et al.  Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer , 2016, Cell.

[19]  E. Oki,et al.  Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis , 2016, Oncology.

[20]  Qiuhong Wang,et al.  Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis. , 2016, Experimental and molecular pathology.

[21]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[22]  Yoon Young Choi,et al.  Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives , 2015, Journal of pathology and translational medicine.

[23]  F. Qiu,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis , 2015, Clinical and Translational Oncology.

[24]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[25]  Doriano Fabbro,et al.  Ten things you should know about protein kinases: IUPHAR Review 14 , 2015, British journal of pharmacology.

[26]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[27]  Jiyeon Kim,et al.  The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies , 2015, Front. Pharmacol..

[28]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[29]  J. Ajani,et al.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Joel,et al.  Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells , 2013, Science Signaling.

[31]  Zhengyan Kan,et al.  Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer , 2011, Nature Genetics.

[32]  Chia Huey Ooi,et al.  Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. , 2011, Gastroenterology.

[33]  Edward L Huttlin,et al.  Correct Interpretation of Comprehensive Phosphorylation Dynamics Requires Normalization by Protein Expression Changes* , 2011, Molecular & Cellular Proteomics.

[34]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[35]  S. Sorscher.  FDA-approved drugs. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[36]  B. Kuster,et al.  Confident Phosphorylation Site Localization Using the Mascot Delta Score , 2010, Molecular & Cellular Proteomics.

[37]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[38]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[39]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[40]  V. Pankratz,et al.  Lymphocyte-Rich Gastric Cancer: Associations with Epstein-Barr Virus, Microsatellite Instability, Histology, and Survival , 2003, Modern Pathology.

[41]  B. Henderson.  Post-Transcriptional Regulation , 2002 .

[42]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[43]  Peng Wu,et al.  Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. , 2016, Drug discovery today.

[44]  C. Eyers.  Universal sample preparation method for proteome analysis , 2009 .

[45]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.